Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment
Immune checkpoint inhibitors (ICIs) have revolutionized the clinical management of multiple
tumours. However, only a few patients respond to ICIs, which has generated considerable …
tumours. However, only a few patients respond to ICIs, which has generated considerable …
Immunomodulation by targeted anticancer agents
At odds with conventional chemotherapeutics, targeted anticancer agents are designed to
inhibit precise molecular alterations that support oncogenesis or tumor progression. Despite …
inhibit precise molecular alterations that support oncogenesis or tumor progression. Despite …
Control of metastasis by NK cells
The metastatic spread of malignant cells to distant anatomical locations is a prominent
cause of cancer-related death. Metastasis is governed by cancer-cell-intrinsic mechanisms …
cause of cancer-related death. Metastasis is governed by cancer-cell-intrinsic mechanisms …
Immunological effects of conventional chemotherapy and targeted anticancer agents
The tremendous clinical success of checkpoint blockers illustrates the potential of
reestablishing latent immunosurveillance for cancer therapy. Although largely neglected in …
reestablishing latent immunosurveillance for cancer therapy. Although largely neglected in …
Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell–driven tumor immunity
MICA and MICB are expressed by many human cancers as a result of cellular stress, and
can tag cells for elimination by cytotoxic lymphocytes through natural killer group 2D …
can tag cells for elimination by cytotoxic lymphocytes through natural killer group 2D …
Non-genomic and immune evolution of melanoma acquiring MAPKi resistance
Clinically acquired resistance to MAPK inhibitor (MAPKi) therapies for melanoma cannot be
fully explained by genomic mechanisms and may be accompanied by co-evolution of intra …
fully explained by genomic mechanisms and may be accompanied by co-evolution of intra …
The NK cell granule protein NKG7 regulates cytotoxic granule exocytosis and inflammation
Immune-modulating therapies have revolutionized the treatment of chronic diseases,
particularly cancer. However, their success is restricted and there is a need to identify new …
particularly cancer. However, their success is restricted and there is a need to identify new …
Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma
S Kakadia, N Yarlagadda, R Awad… - OncoTargets and …, 2018 - Taylor & Francis
Approximately 50% of melanomas harbor an activating BRAF mutation. Combined BRAF
and MEK inhibitors such as dabrafenib and trametinib, vemurafenib and cobimetinib, and …
and MEK inhibitors such as dabrafenib and trametinib, vemurafenib and cobimetinib, and …
Co-inhibition of CD73 and A2AR adenosine signaling improves anti-tumor immune responses
A Young, SF Ngiow, DS Barkauskas, E Sult, C Hay… - Cancer cell, 2016 - cell.com
Preclinical studies targeting the adenosinergic pathway have gained much attention for their
clinical potential in overcoming tumor-induced immunosuppression. Here, we have …
clinical potential in overcoming tumor-induced immunosuppression. Here, we have …
CIS is a potent checkpoint in NK cell–mediated tumor immunity
RB Delconte, TB Kolesnik, LF Dagley, J Rautela… - Nature …, 2016 - nature.com
The detection of aberrant cells by natural killer (NK) cells is controlled by the integration of
signals from activating and inhibitory ligands and from cytokines such as IL-15. We identified …
signals from activating and inhibitory ligands and from cytokines such as IL-15. We identified …